Hologic completed the acquisition of Diagenode for $159m.

Hologic, a women's health company, completed the acquisition of Diagenode, a European developer and manufacturer of molecular diagnostic assays and epigenetics products, for $159m. “Acquiring Diagenode further strengthens our molecular diagnostics business by expanding our international capabilities, improving our regional time-to-market, and allowing us to offer a broader, more differentiated test menu,” Jan Verstreken, Hologic Group President.